Female Reproductive & Breast

BRCA1/2 mutations: screening, prophylaxis, counseling

Clinical Overview and When to Suspect Hereditary Breast/Ovarian Cancer Syndrome

— Breast cancer: BRCA1 ~55–72%, BRCA2 ~45–69% (vs ~13% general population)

— Ovarian/fallopian/peritoneal: BRCA1 ~39–44%, BRCA2 ~11–17%

— Male breast cancer: BRCA2 ~7% (BRCA1 ~1%)

— Prostate cancer (BRCA2 > BRCA1), pancreatic cancer (~3–7%), melanoma (BRCA2)

— Breast cancer diagnosed age <50, triple-negative <60, or bilateral

— Male breast cancer at any age

— Ovarian/fallopian/primary peritoneal cancer at any age

— ≥2 relatives on same lineage with breast, ovarian, pancreatic, or aggressive prostate cancer

— Ashkenazi Jewish ancestry with any of the above (founder mutations: BRCA1 185delAG, 5382insC; BRCA2 6174delT — ~1 in 40 carrier frequency)

— Known pathogenic variant in the family

BRCA1/2 are tumor suppressor genes on chromosomes 17q21 and 13q12 encoding proteins essential for homologous recombination DNA repair; pathogenic loss-of-function variants follow autosomal dominant inheritance with incomplete penetrance.

Lifetime cancer risks (pathogenic variant carriers):

When to suspect (red flags in family/personal history):

USPSTF (2019, Grade B): primary care clinicians should screen women with personal or family history of breast, ovarian, tubal, or peritoneal cancer—or ancestry associated with BRCA mutations—using a validated familial risk tool (e.g., Ontario Family History Assessment Tool, Manchester Scoring, PREMM, BRCAPRO, Tyrer-Cuzick). Positive screen → genetic counseling, then testing if indicated.

Step 3 management: Do not order BRCA testing as a first step in the office. The correct sequence is risk-assessment tool → referral to genetic counselor → informed consent → targeted or panel testing. Ordering testing without counseling is a frequently penalized misstep on exam vignettes.

Board pearl: Negative family history does not exclude a mutation—up to ~50% of carriers identified by population screening in Ashkenazi cohorts lacked classic family history flags.

Presentation Patterns and Key History

— Affected proband: young woman newly diagnosed with breast or ovarian cancer

— Unaffected relative of a known carrier or cancer-affected family member

— Population/ancestry-based screen (e.g., Ashkenazi Jewish patient requesting testing)

— Document maternal AND paternal lineages (BRCA can be inherited from father; commonly missed)

— Ages at diagnosis, primary site (not just "cancer"), bilaterality, pathology subtype (triple-negative, high-grade serous ovarian)

— Ethnicity (Ashkenazi Jewish, Icelandic, French-Canadian founder populations)

— Prior genetic testing in relatives—always request the documented report, not patient recall

— Premenopausal breast cancer, contralateral breast cancer, triple-negative breast cancer <60

— Epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (any age, any histology except mucinous/borderline)

— Pancreatic adenocarcinoma, metastatic or high-risk prostate cancer (Gleason ≥7)

— Parity, age at menarche/menopause, breastfeeding duration

— Oral contraceptive use (reduces ovarian cancer risk ~50% in carriers; small increase in breast cancer risk—net benefit favorable in young carriers)

— Prior chest radiation (Hodgkin survivors compound breast risk)

Most BRCA carriers are asymptomatic at the time of identification; presentation is typically through one of three doorways on Step 3:

Three-generation pedigree is the single most important history element:

Personal history clues:

Reproductive/hormonal history (modifies risk and affects counseling):

Key distinction: A patient with a known pathogenic familial variant needs single-site testing for that exact variant only—not a full BRCA sequencing panel. This is cheaper, faster, and the boards-correct answer. Reflex to "comprehensive panel" only if proband testing has not yet been done or initial single-site is negative but suspicion remains very high.

Board pearl: Mucinous and borderline ovarian tumors are not part of the BRCA spectrum—don't let them anchor the diagnosis.

Physical Exam Findings and Pre-Test Assessment

— Clinical breast exam every 6–12 months starting age 25 in carriers (NCCN)

— Document breast size, density estimate, skin/nipple changes, axillary and supraclavicular nodes

— Note prior biopsies, scars, implants (affects MRI interpretation)

— Teach breast self-awareness (not formal monthly BSE — evidence does not support mortality benefit, but awareness of new changes is encouraged)

— Bimanual and speculum exam; limited sensitivity for early ovarian cancer but documents baseline

— Note adnexal masses, ascites, omental caking (late findings)

— Skin exam for melanoma screening (BRCA2)

— In men: testicular exam, prostate considerations (DRE per shared decision-making starting age 40 in BRCA2)

— BMI, blood pressure (baseline for future estrogen-related decisions)

— Patient's understanding of hereditary cancer, motivations, expectations

— Mental health history—active untreated depression or suicidality is a relative contraindication to immediate testing; stabilize first

— Reproductive plans (impacts timing of risk-reducing salpingo-oophorectomy)

— Insurance status and GINA awareness (see Chunk 17)

BRCA carriers are usually physically normal; the exam serves as a baseline and to detect occult disease before initiating surveillance or risk-reducing surgery.

Breast exam:

Pelvic exam:

General:

Pre-test psychosocial assessment (do before ordering test):

Step 3 management: Before sending the test, document pre-test counseling: inheritance pattern, possible results (positive, negative, variant of uncertain significance), implications for relatives, surveillance vs surgery options, and psychological impact. This documentation is both ethically required and the boards-expected answer.

Board pearl: A normal exam never substitutes for imaging surveillance in a high-risk patient—reassurance without MRI/mammography is wrong in the BRCA carrier vignette.

Diagnostic Workup — Genetic Testing Logistics and Initial Evaluation

— A cancer-affected family member is most likely to have an identifiable pathogenic variant

— If affected relative tests negative, testing the unaffected proband is low yield (uninformative negative)

— If affected relative is unavailable, test the unaffected highest-risk relative

— Known familial pathogenic variant → single-site targeted analysis

— Ashkenazi Jewish with no known family variant → three-mutation founder panel first (cheaper); if negative and suspicion remains, full sequencing

— Unknown variant, broad family history → multigene panel (BRCA1/2 + PALB2, CHEK2, ATM, TP53, PTEN, CDH1, STK11) — increasingly the default

— Full gene sequencing (detects point mutations, small indels)

— Large rearrangement testing (BART/MLPA) — detects large deletions/duplications missed by sequencing; must be included or result is incomplete

— Pathogenic / likely pathogenic: actionable—proceed with management plan

— Benign / likely benign: reassure; manage by family history alone

— Variant of uncertain significance (VUS): do not alter management based on a VUS; manage per family history; re-contact lab periodically for reclassification

— CBC, CMP, lipid panel, vitamin D, TSH

— Pregnancy test before imaging/surgery in reproductive-age women

Test the affected relative first whenever possible:

Test selection:

Components of comprehensive BRCA analysis:

Specimen: peripheral blood or buccal/saliva; both acceptable

Result categories:

Adjunct labs at baseline (before any surgical or pharmacologic prevention):

Key distinction: A VUS is not a positive result. Vignettes often try to trick you into recommending mastectomy or oophorectomy for a VUS—wrong answer. Manage VUS patients based on personal/family history only.

Board pearl: Direct-to-consumer (23andMe) tests only screen the three Ashkenazi founder mutations—a negative DTC result does not rule out BRCA mutation in non-Ashkenazi or even Ashkenazi patients with broader variants.

Diagnostic Workup — Surveillance Imaging Protocols

— Age 25–29: annual breast MRI with contrast (preferred—higher sensitivity in dense young breasts and lower radiation)

— Age 30–75: annual mammogram with tomosynthesis AND annual breast MRI, typically alternating every 6 months (e.g., MRI in January, mammogram in July) so the breast is imaged every 6 months

— Age >75: individualized

— Clinical breast exam every 6–12 months from age 25

— No imaging or biomarker has been proven to reduce ovarian cancer mortality

— May consider transvaginal ultrasound and CA-125 every 6 months starting age 30–35, but emphasize this is inadequate—the definitive risk-reducing strategy is bilateral salpingo-oophorectomy

— Consider annual MRI/MRCP or endoscopic ultrasound starting age 50 (or 10 years before youngest affected relative) only if ≥1 first-/second-degree relative with pancreatic cancer

— BRCA2: annual PSA + DRE starting age 40

— BRCA1: consider starting age 40 (weaker evidence)

— Monthly self-exam and annual clinical breast exam from age 35

— Consider annual mammogram in BRCA2 men with gynecomastia or dense parenchyma

Once a pathogenic BRCA1/2 variant is confirmed, enhanced surveillance begins immediately for those not pursuing immediate prophylactic surgery.

Breast surveillance (NCCN guidelines):

Ovarian surveillance:

Pancreatic surveillance (BRCA2 > BRCA1):

Prostate surveillance (men):

Male breast surveillance:

Melanoma: annual full-body skin exam (BRCA2)

Step 3 management: A 28-year-old BRCA1 carrier asks about screening. Correct answer: annual breast MRI now; add mammography at age 30. Do not start mammography at 25—the radiation risk in young BRCA carriers may increase breast cancer risk and MRI has superior sensitivity.

Board pearl: Ovarian "screening" with TVUS/CA-125 is not effective—boards reward acknowledging this limitation and steering toward risk-reducing surgery by age 35–40 (BRCA1) or 40–45 (BRCA2).

Risk Stratification and Management Decision Framework

— Enhanced surveillance (as in Chunk 5)

— Chemoprevention (pharmacologic risk reduction)

— Risk-reducing surgery (mastectomy, salpingo-oophorectomy)

— Age and reproductive plans (family complete? planning pregnancy?)

— Specific gene (BRCA1 vs BRCA2—different cancer spectrum and timing)

— Family history specifics (age of onset in relatives often informs timing)

— Comorbidities and surgical candidacy

— Patient values (body image, cancer anxiety, fertility, surgical menopause tolerance)

— BRCA1: recommended age 35–40, after childbearing complete

— BRCA2: recommended age 40–45 (ovarian cancer onset ~8–10 years later than BRCA1)

— Reduces ovarian cancer risk 80–96% and breast cancer risk ~50% if premenopausal at surgery

— All-cause mortality reduction demonstrated

— Reduces breast cancer risk >90%

— Bilateral total (simple) mastectomy ± nipple-sparing; usually with immediate reconstruction

— Does not improve overall survival as robustly as RRBSO in modeling—offered as patient-preference option

— Tamoxifen (premenopausal/postmenopausal) or raloxifene/aromatase inhibitor (postmenopausal) reduces ER-positive breast cancer

— Greater benefit in BRCA2 (more ER-positive tumors); modest in BRCA1 (mostly triple-negative)

— Combined OCPs reduce ovarian cancer risk ~50% in carriers—offer to young carriers who have not had RRBSO

Three management arms after a confirmed pathogenic BRCA1/2 variant:

Decision drivers:

Risk-reducing bilateral salpingo-oophorectomy (RRBSO):

Risk-reducing mastectomy (RRM):

Chemoprevention:

Step 3 management: For a 36-year-old BRCA1 carrier with two children, family complete: recommend RRBSO now, offer RRM, and continue breast MRI/mammography until RRM. Delaying RRBSO past age 40 in BRCA1 is the wrong answer.

Board pearl: RRBSO before natural menopause is the single intervention with the strongest mortality benefit in BRCA carriers.

Pharmacotherapy — Chemoprevention and Hormonal Considerations

— Dose: 20 mg PO daily × 5 years

— Reduces invasive ER-positive breast cancer ~50%

— Eligible: women ≥35 with elevated risk (Gail/Tyrer-Cuzick 5-year risk ≥1.67%, or BRCA carrier)

— Side effects: VTE, endometrial cancer (postmenopausal), hot flashes, cataracts

— Contraindications: prior VTE, stroke/TIA, pregnancy, planned pregnancy

— Monitor: annual gynecologic exam, prompt evaluation of postmenopausal bleeding

— Reduce ovarian cancer ~50% per 5 years of use in BRCA carriers

— Small absolute increase in breast cancer risk

— Net benefit favorable in young carriers (under 35) without contraindications

— Avoid in women with prior breast cancer

— In premenopausal BRCA carriers undergoing RRBSO who have no personal history of breast cancer, short-term HRT (until ~age 50–51) is acceptable and recommended to manage surgical menopause symptoms and protect bone/CV health

— Does not appear to negate breast cancer risk reduction from RRBSO

— Use estrogen-only if hysterectomized; estrogen + progestin if uterus retained (slightly higher breast risk—favor hysterectomy at time of RRBSO if patient agrees)

— Contraindicated after a personal history of breast cancer

Tamoxifen (selective estrogen receptor modulator):

Raloxifene: postmenopausal only; lower endometrial cancer risk than tamoxifen; less effective for invasive cancer reduction

Aromatase inhibitors (exemestane, anastrozole): postmenopausal; reduce breast cancer ~65% (MAP.3, IBIS-II); monitor bone density and joint pain; not FDA-approved for prevention but guideline-endorsed

Combined oral contraceptives:

Hormone replacement therapy (HRT) after RRBSO:

PARP inhibitors (olaparib, talazoparib): treatment, not prevention—reserved for BRCA-associated breast, ovarian, pancreatic, prostate cancers

Step 3 management: A 42-year-old BRCA2 carrier post-RRBSO with severe vasomotor symptoms and no breast cancer history → start low-dose estrogen-only HRT (assuming prior hysterectomy) until age ~51. Refusing HRT is a common wrong answer.

Board pearl: Tamoxifen is category D in pregnancy—confirm negative pregnancy test and ensure contraception during and 2 months after therapy.

Risk-Reducing Surgery — Procedural Details and Timing

— Laparoscopic standard; remove both ovaries and entire fallopian tubes (high-grade serous "ovarian" cancers often originate in fallopian tube fimbria)

— SEE-FIM pathology protocol: serial sectioning and extensive examination of fimbriated end

— Peritoneal washings at time of surgery

— Counsel: surgical menopause consequences—vasomotor symptoms, bone loss, sexual dysfunction, cardiovascular risk, cognitive changes

— Residual primary peritoneal cancer risk ~1–4% remains lifelong post-RRBSO

— Concurrent hysterectomy: not mandatory; consider if planning tamoxifen, fibroids, or estrogen-only HRT preference

— Timing: BRCA1 age 35–40, BRCA2 age 40–45, after childbearing

— Investigational alternative for women not ready for surgical menopause

— Not yet standard of care; only in clinical trial settings

— Bilateral total (simple) mastectomy ± nipple-sparing (preserves nipple-areolar complex if oncologically safe)

— Immediate reconstruction options: implant-based (one- or two-stage) or autologous (DIEP flap most common)

— Residual breast cancer risk <5% lifetime

— Counsel: loss of nipple sensation, multiple surgeries possible, capsular contracture, does not improve survival as decisively as RRBSO

— Contralateral prophylactic mastectomy after unilateral breast cancer in BRCA carrier: strongly considered (reduces contralateral cancer but not necessarily overall survival)

Risk-reducing bilateral salpingo-oophorectomy (RRBSO):

Salpingectomy with delayed oophorectomy:

Risk-reducing mastectomy (RRM):

Pre-op workup: baseline breast MRI within 6 months (rule out occult cancer), pregnancy test, anesthesia clearance

CCS pearl: On a CCS case of a BRCA1 carrier post-childbearing, advance the clock: order pre-op labs, schedule RRBSO, then post-op give DVT prophylaxis, monitor for surgical menopause symptoms, and start HRT if no contraindication. Document genetic counselor referral for family cascade testing.

Board pearl: Always remove the entire fallopian tube—stump retention defeats the purpose because most "ovarian" cancers in BRCA carriers arise from tubal fimbria.

Special Populations — Elderly and Renal/Hepatic Considerations

— Cancer risk reduction benefit from RRBSO diminishes—ovarian cancer risk peaks earlier; most benefit lost after natural menopause

— Continue annual mammography; MRI may be added based on density and comorbidity

— Life expectancy >10 years is the threshold for aggressive prophylactic measures

— Avoid initiating chemoprevention if life expectancy <10 years or competing comorbidity dominates risk

— Tamoxifen: no major dose adjustment; monitor for fluid retention

— Aromatase inhibitors: generally safe; monitor bone density (BMD baseline + every 2 years; calcium, vitamin D, bisphosphonate as needed)

— Gadolinium MRI contrast: avoid in eGFR <30 (nephrogenic systemic fibrosis); use mammography + ultrasound alternative

— Tamoxifen is hepatically metabolized via CYP2D6 to endoxifen (active metabolite); avoid with severe hepatic dysfunction

— Drug interactions: strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion) reduce tamoxifen efficacy—switch to venlafaxine or citalopram for hot flashes or depression in patients on tamoxifen

— Monitor LFTs at baseline and periodically

— Defer or simplify surveillance if competing mortality risk is high

— Shared decision-making with patient and family

— Verify capacity to consent for genetic testing and surgical decisions

— Involve surrogate decision-maker per state law if capacity lacking

Older newly diagnosed carriers (women identified at age >60–70):

Renal impairment:

Hepatic impairment:

Frailty and comorbidity:

Cognitive impairment:

Step 3 management: A 72-year-old newly diagnosed BRCA2 carrier with mild CKD asks about RRBSO. After natural menopause, ovarian cancer risk reduction benefit is small; discuss but do not push surgery; continue mammography ± MRI; avoid AIs without DEXA monitoring.

Board pearl: Paroxetine + tamoxifen = bad combo. This drug-interaction question appears frequently. Use venlafaxine for vasomotor symptoms in tamoxifen users.

Special Populations — Pregnancy, Pediatrics, and Men

— BRCA testing is safe during pregnancy (blood draw only) but counseling about timing is important—results affect breastfeeding, postpartum surgery planning

— Preimplantation genetic testing (PGT-M) is offered to BRCA carriers desiring biological children without transmitting the variant—discuss with reproductive endocrinology

— Pregnancy itself does not accelerate BRCA cancer risk; breastfeeding ≥1 year reduces breast cancer risk in BRCA1 carriers

— Tamoxifen is contraindicated in pregnancy and during attempts to conceive

— RRBSO causes immediate infertility; counsel on oocyte/embryo cryopreservation before surgery if fertility desired

— Do not test minors for BRCA1/2—no childhood cancer risk, and testing violates the child's future autonomy/right to an open future

— Exception: testing may be considered if a syndrome with childhood cancer risk is also in differential (e.g., Li-Fraumeni TP53 — different gene, but panel testing context)

— Begin discussions in late adolescence; testing typically offered at age 18–25

— BRCA2 carries higher male cancer risk

— Breast self-exam monthly from age 35; clinical breast exam annually

— PSA + DRE annually from age 40 (BRCA2; consider for BRCA1)

— Annual skin exam (melanoma in BRCA2)

— Pancreatic surveillance if family history

— Cascade testing: men can transmit BRCA to daughters with the same 50% risk—frequently underrecognized

— Educate about family history and future testing; defer testing until adulthood

Pregnancy and fertility:

Pediatric considerations:

Men with BRCA mutations:

Adolescent daughters of carriers:

Step 3 management: A 19-year-old asks for BRCA testing because her mother is a carrier. Refer to genetic counseling; testing is appropriate once she reaches the age where surveillance would begin (~25). Do not refuse outright, but do not test reflexively either.

Board pearl: Fathers transmit BRCA mutations 50% of the time—don't ignore the paternal pedigree.

Complications and Adverse Outcomes

— Vasomotor symptoms: hot flashes, night sweats—treat with HRT (if no contraindication), SSRIs/SNRIs (venlafaxine, escitalopram), gabapentin, oxybutynin

— Genitourinary syndrome of menopause: vaginal dryness, dyspareunia—topical estrogen safe even after breast cancer in many cases (shared decision)

— Bone loss: DEXA baseline + every 2 years; calcium 1200 mg, vitamin D 800–1000 IU; bisphosphonate if osteoporosis

— Cardiovascular risk: accelerated atherosclerosis; aggressive lipid and BP management

— Cognitive effects: subjective memory complaints common; HRT may mitigate

— Sexual dysfunction: decreased libido, arousal—address with lubricants, vaginal estrogen, possibly testosterone (off-label)

— Infection, hematoma, seroma, skin necrosis (especially nipple-sparing)

— Implant complications: capsular contracture, rupture, BIA-ALCL (textured implants—rare lymphoma; FDA recall)

— Chronic pain, lymphedema (less if no axillary dissection)

— Psychological: body image distress, depression, regret (~5% of patients)

— Tamoxifen: VTE risk ~1–2%, endometrial cancer ~0.5%/year in postmenopausal users, cataracts, hot flashes

— AIs: arthralgia, bone loss, hyperlipidemia

— False positives → biopsies, anxiety

— Cumulative radiation (mammography in young women)—mitigated by MRI-first strategy <30

— Anxiety, depression, "previvor" identity, family conflict over testing, survivor guilt in negative-tested family members

Surgical menopause (post-RRBSO in premenopausal women):

Mastectomy complications:

Chemoprevention adverse events:

Surveillance harms:

Psychosocial:

Residual cancer risk despite all measures: peritoneal carcinomatosis ~1–4% post-RRBSO; contralateral or chest wall recurrence <5% post-RRM

CCS pearl: Post-RRBSO patient returns at 6 weeks with hot flashes and insomnia—order DEXA, start HRT if no breast cancer history, counsel on lifestyle, schedule follow-up in 3 months.

Board pearl: Postmenopausal bleeding on tamoxifen = endometrial biopsy, every time.

When to Escalate Care — Referrals and Multidisciplinary Coordination

— Comprehensive pedigree analysis

— Pre- and post-test counseling

— Variant interpretation and family cascade testing coordination

— Updates on VUS reclassification

— All confirmed carriers—even those choosing surveillance

— Coordinates MRI/mammography, biopsy if abnormal findings

— Discusses risk-reducing mastectomy

— RRBSO with proper SEE-FIM pathology

— Management of any abnormal pelvic findings

— Surveillance counseling

— Chemoprevention selection and monitoring

— Treatment if cancer develops (PARP inhibitor candidacy)

— Fertility preservation before RRBSO

— PGT-M discussion

— Reconstruction planning if pursuing mastectomy

— Pre-test if active mood or anxiety disorder

— Post-result for adjustment, decision regret, family stress

— PSA elevation, prostate biopsy in BRCA2 carriers

— New ovarian mass with ascites, weight loss → admit, gyn-onc consult, CT chest/abd/pelvis, CA-125, paracentesis

— Breast cancer diagnosis → outpatient oncology referral within 1–2 weeks; admit only if complications (cord compression, malignant effusion, hypercalcemia)

Genetic counselor / clinical geneticist referral (mandatory before testing in most cases):

High-risk breast clinic / breast surgeon:

Gynecologic oncologist (not general OB-GYN):

Medical oncologist:

Reproductive endocrinology:

Plastic surgery:

Mental health:

Urologist (men):

Inpatient escalation (for the affected proband):

Step 3 management: A primary care clinician identifies a 32-year-old BRCA1 carrier via cascade testing. Next steps in order: (1) genetic counselor confirmation visit, (2) high-risk breast clinic for MRI scheduling, (3) gyn-oncology consult for RRBSO planning by age 35–40, (4) mental health resources, (5) discuss cascade testing for first-degree relatives.

Board pearl: RRBSO should be performed by a gynecologic oncologist using the SEE-FIM protocol, not a general gynecologist—this is a frequently tested quality-of-care point.

Key Differentials — Other Hereditary Breast/Ovarian Cancer Syndromes

— Breast cancer risk approaching BRCA2 (~35–55% lifetime); pancreatic and ovarian also elevated

— Manage similarly to BRCA2 for breast; RRBSO controversial—consider age 45–50 if family history of ovarian

— Early-onset breast cancer (<30), sarcomas, brain tumors, adrenocortical carcinoma, leukemia

— Surveillance includes annual whole-body MRI, breast MRI from age 20

— Avoid radiation (including mammography until ≥30) due to radiation-induced cancers

— Breast, thyroid, endometrial cancers; macrocephaly, mucocutaneous lesions (trichilemmomas), hamartomatous polyps

— Lobular breast cancer + diffuse gastric cancer; prophylactic gastrectomy and bilateral mastectomy discussions

— Mucocutaneous pigmentation, GI hamartomas, breast/ovarian/pancreatic/cervical cancers

— Moderate breast cancer risk (~20–30% lifetime); annual MRI from age 40; usually no risk-reducing mastectomy unless additional factors

— Colorectal and endometrial cancers dominant; ovarian risk elevated (especially MSH2, MSH6); not classically a breast cancer syndrome

— BRCA1: triple-negative breast cancer, high-grade serous ovarian, earlier onset

— BRCA2: ER-positive breast (incl. male breast), pancreatic, melanoma, prostate

— TP53: childhood and very-early-onset diverse cancers—think Li-Fraumeni if breast cancer <30 with family sarcoma or brain tumor

— PTEN: breast + thyroid + macrocephaly

PALB2 (partner and localizer of BRCA2):

TP53 (Li-Fraumeni syndrome):

PTEN (Cowden syndrome):

CDH1 (hereditary diffuse gastric cancer):

STK11 (Peutz-Jeghers):

CHEK2, ATM:

Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM):

Key distinction:

Step 3 management: A 26-year-old with breast cancer, sarcoma in a sibling, and adrenocortical carcinoma in a parent → suspect Li-Fraumeni (TP53), not BRCA. Order multigene panel including TP53; avoid mammography pre-30.

Board pearl: Multigene panel testing is now first-line over BRCA-only testing for most hereditary breast/ovarian cancer evaluations because of these overlapping syndromes.

Key Differentials — Sporadic and Non-Hereditary High-Risk Categories

— Up to 70% of familial clustering has no identifiable single-gene cause

— Manage by empiric risk calculation (Tyrer-Cuzick, Gail) — if lifetime risk ≥20%, qualify for annual breast MRI in addition to mammography

— Consider chemoprevention if 5-year Gail risk ≥1.67%

— Independent risk factor (~1.2–2× relative risk)

— Many states mandate density notification; supplemental MRI or ultrasound considered for category C/D density with other risk factors

— Risk approaches BRCA carrier levels

— Annual MRI + mammography starting 8 years after radiation or age 25, whichever later

— 4–10× relative risk

— Strong indication for chemoprevention (tamoxifen reduces risk ~75% in atypical hyperplasia)

— Early menarche, late menopause, nulliparity, late first birth, HRT use, obesity (postmenopausal), alcohol >1 drink/day

— Limit alcohol, maintain healthy BMI, regular exercise (≥150 min/week moderate), breastfeed when possible, avoid unnecessary HRT

— Most cases are sporadic; population screening with CA-125/TVUS is not recommended (PLCO and UKCTOCS showed no mortality benefit)

Family history without identifiable mutation ("familial breast cancer"):

Dense breast tissue:

Prior chest radiation (e.g., Hodgkin lymphoma treated age 10–30):

Atypical hyperplasia / lobular carcinoma in situ (LCIS) on prior biopsy:

Reproductive/lifestyle factors (modifiers, not differentials):

Modifiable risk reduction (counsel all patients, BRCA or not):

Sporadic ovarian cancer:

Key distinction: A patient with strong family history but negative comprehensive panel is still at elevated empiric risk—manage by family-history-based protocols (often MRI eligibility), don't dismiss as average risk.

Step 3 management: A 35-year-old woman with mother and aunt having breast cancer at 45 tests negative on BRCA panel. Tyrer-Cuzick lifetime risk = 25%. Correct plan: annual mammography + annual MRI, consider tamoxifen, lifestyle counseling. The negative test does not erase her risk.

Board pearl: 20% lifetime risk is the magic threshold for adding annual breast MRI to mammography per ACS guidelines.

Long-Term Plan and Cascade Testing

— Once a pathogenic variant is identified in a proband, all first-degree relatives (parents, siblings, children ≥18) should be offered targeted single-site testing

— Extend to second-degree relatives on the affected side if intermediate relative declines

— Both sexes equally important—men inherit and transmit BRCA at the same rate

— Health system responsibility: provide proband with family letter summarizing the variant and testing instructions; protect privacy by letting proband contact relatives

— Personalized survivorship/previvor care plan: written summary of mutation, surveillance schedule, surgery plans, chemoprevention

— Annual review with primary care + high-risk specialist

— Update family pedigree annually—new diagnoses change risk

— HRT until age 50–51 (natural menopause age) if no breast cancer history

— Bone health: DEXA q2 years, calcium/vitamin D, weight-bearing exercise

— Cardiovascular: lipid panel, BP, ASCVD risk every 1–2 years

— Sexual health: continue vaginal estrogen as needed

— Annual chest wall exam; no mammography needed

— Implant surveillance per plastic surgery (MRI for silicone implant integrity per FDA—5–6 years post-op then q2–3 years)

— Colonoscopy per average-risk guidelines (BRCA does not significantly increase CRC risk)

— Cervical cancer screening per USPSTF (unchanged)

— Vaccinations: HPV, influenza, COVID, age-appropriate

Cascade testing of relatives:

Longitudinal management plan for confirmed carriers:

Post-RRBSO long-term issues:

Post-RRM long-term:

General preventive care (don't forget these on Step 3):

Step 3 management: At every annual visit, ask about new cancer diagnoses in relatives and update the management plan. A newly diagnosed pancreatic cancer in a parent of a BRCA2 carrier triggers consideration of pancreatic surveillance starting age 50.

Board pearl: Cascade testing yields the highest value-per-dollar in cancer genetics; coordinating it is a Step 3 health-systems point.

Follow-Up, Monitoring, and Counseling Cadence

— Breast MRI annually (typically at 6-month offset from mammography)

— Mammography with tomosynthesis annually from age 30

— Clinical breast exam every 6–12 months

— Pelvic exam annually; TVUS + CA-125 every 6 months if delaying RRBSO past recommended age (low-yield but better than nothing)

— Tamoxifen: annual gynecologic exam; investigate any postmenopausal bleeding; baseline ophthalmologic exam if symptoms

— AIs: DEXA baseline + every 2 years; lipid panel annually

— Document medication adherence at each visit

— 2-week post-op visit (wound check)

— 6-week visit (menopausal symptom assessment, start HRT if appropriate)

— 6-month visit (HRT titration, bone/CV baseline)

— Annually thereafter: HRT review, DEXA q2 years, lipid annually, no routine CA-125 needed (no proven peritoneal surveillance benefit)

— Plastic surgery follow-up per reconstruction protocol

— Annual chest wall exam by surgeon or PCP

— Address psychosocial adjustment, sexual function

— Annual genetic update visit—ask about VUS reclassification, new family cancers, new guideline updates

— Document shared decision-making at each major branch point

— Symptom awareness (breast lump, bloating/early satiety/pelvic pain for ovarian)

— Adherence to imaging schedule (no-show rates ~20%—follow up actively)

— Family communication and cascade testing reinforcement

Pre-prophylactic-surgery surveillance cadence:

On chemoprevention monitoring:

Post-RRBSO monitoring:

Post-RRM monitoring:

Counseling cadence:

Patient education themes:

CCS pearl: Advance the simulated clock—after RRBSO order DEXA at 6 weeks, lipid panel at 3 months, follow-up visit at 6 months, and start HRT at the 6-week visit if indicated.

Board pearl: Even after RRBSO, carriers still need breast surveillance unless they have also had RRM.

Ethical, Legal, and Patient Safety Considerations

— Voluntariness, possible results (positive, negative, VUS), implications for self and biological relatives, surveillance/surgical options, psychological impact, insurance and privacy issues, right to refuse, alternatives

— Document the discussion explicitly

— Prohibits health insurance and employer discrimination based on genetic information

— Does NOT cover life insurance, disability insurance, or long-term care insurance—patients may want to secure these policies before testing

— Does not cover military, Indian Health Service, or some self-insured plans completely

— Patient holds primary responsibility to inform at-risk relatives; clinicians strongly encourage but typically cannot directly contact relatives without patient consent (HIPAA)

— Provide family letter; document patient agreement to share

— Limited case law supports duty to warn in extreme circumstances—jurisdiction-specific

— Generally defer until age of majority for adult-onset cancer genes—respects future autonomy

— Exception: childhood-onset syndromes

— Do not act surgically on a VUS—a frequently tested ethical/safety pitfall

— Reclassification possible over time; periodic lab re-contact

— Limited variant panels (e.g., 3-mutation Ashkenazi panel only on 23andMe)

— False reassurance; clinical confirmation required for any actionable result

— Carrier moving to new PCP: ensure genetic report, surveillance schedule, and family pedigree are transferred; discontinuity of surveillance is a real harm

— Verify capacity for major decisions (surgery, chemoprevention)

— PGT-M, prenatal diagnosis, adoption, and not testing are all valid; clinician role is to inform, not direct

Informed consent for genetic testing (mandatory pre-test):

Genetic Information Nondiscrimination Act (GINA, 2008):

Duty to warn relatives:

Testing minors:

Variants of uncertain significance:

Direct-to-consumer testing pitfalls:

Transition-of-care safety:

Capacity and surrogate decisions:

Reproductive autonomy:

Step 3 management: A patient asks whether to buy life insurance before genetic testing. Correct counseling: GINA does not protect life/disability insurance—consider securing policies before testing if relevant to family planning.

Board pearl: Acting on a VUS as if it were pathogenic = malpractice-flavored wrong answer.

High-Yield Associations and Rapid-Fire Clinical Facts

BRCA1 chromosome 17q21; BRCA2 chromosome 13q12—both tumor suppressors in homologous recombination repair

BRCA1 cancers: triple-negative, high-grade, basal-like; often medullary histology; earlier onset

BRCA2 cancers: ER-positive breast (similar to sporadic); strongest gene for male breast cancer, pancreatic, melanoma, prostate

Ashkenazi Jewish founder mutations: BRCA1 185delAG, 5382insC; BRCA2 6174delT; carrier frequency ~1 in 40

Lifetime risks: breast ~55–72% (BRCA1), ~45–69% (BRCA2); ovarian 39–44% (BRCA1), 11–17% (BRCA2)

High-grade serous ovarian carcinoma originates in fallopian tube fimbria—rationale for salpingectomy emphasis

SEE-FIM pathology protocol at RRBSO is standard of care

OCP use in BRCA carriers: ~50% ovarian cancer risk reduction per 5 years

Breastfeeding ≥1 year reduces breast cancer in BRCA1 carriers

PARP inhibitors (olaparib, talazoparib, rucaparib, niraparib) exploit synthetic lethality—used for BRCA-mutated ovarian, breast, pancreatic, prostate cancers

Platinum chemotherapy is particularly effective in BRCA-deficient cancers

Tyrer-Cuzick model is most accurate empiric risk calculator for breast cancer; Gail is commonly used but does not incorporate second-degree relatives

20% lifetime breast cancer risk = threshold for adding annual MRI to mammography

Tamoxifen + paroxetine/fluoxetine/bupropion (strong CYP2D6 inhibitors) reduces efficacy—use venlafaxine for hot flashes

GINA protects health insurance and employment, NOT life/disability/long-term care

VUS should not drive surgical decisions

RRBSO age 35–40 BRCA1; 40–45 BRCA2

Pediatric BRCA testing is generally not appropriate

Men with BRCA: PSA from 40 in BRCA2, breast self-exam from 35

Cascade testing: target single-site analysis of known familial variant

Step 3 management: Pattern-recognition: triple-negative breast cancer <60 in any patient = test for BRCA regardless of family history (NCCN criterion).

Board pearl: "Test the affected relative first" is one of the most tested pearls in cancer genetics.

Board Question Stem Patterns

— Answer: Refer for genetic counseling prior to testing—not directly order BRCA test.

— Answer: Risk-reducing bilateral salpingo-oophorectomy now (age 35–40 window).

— Answer: Annual breast MRI with contrast (mammography deferred until age 30 in BRCA2; 30 in BRCA1).

— Answer: Avoid paroxetine; use venlafaxine (does not inhibit CYP2D6).

— Answer: Endometrial biopsy.

— Answer: Do not perform prophylactic mastectomy; manage by family history; recontact lab for reclassification.

— Answer: Start low-dose estrogen-only HRT until age ~51.

— Answer: Refer for genetic counseling; consider BRCA2 testing; do not dismiss paternal lineage.

— Answer: Defer testing until age of majority (~18–25); educate, do not test now.

— Answer: Refer for genetic testing (NCCN criterion: triple-negative <60).

— Answer: GINA does not cover life/disability/LTC—consider securing policies before testing.

Stem 1: 38-year-old Ashkenazi Jewish woman; mother had breast cancer at 42, maternal aunt ovarian cancer at 55. She is asymptomatic. Next step?

Stem 2: Known BRCA1 carrier, 36, two children, family complete. Asks how to reduce ovarian cancer risk.

Stem 3: 28-year-old BRCA2 carrier, no children. Best breast surveillance?

Stem 4: Patient on tamoxifen develops depression; provider considers paroxetine.

Stem 5: Postmenopausal BRCA2 carrier on tamoxifen reports vaginal bleeding.

Stem 6: BRCA panel returns a VUS in a 40-year-old with strong family history.

Stem 7: 42-year-old BRCA1 carrier 6 weeks post-RRBSO with severe hot flashes; no breast cancer history; prior hysterectomy.

Stem 8: Male patient, father had pancreatic cancer at 60, paternal aunt breast cancer at 50. He is 45.

Stem 9: 14-year-old daughter of BRCA1 carrier requests testing.

Stem 10: Newly diagnosed triple-negative breast cancer at age 45 with no family history.

Stem 11: BRCA carrier asks about life insurance before testing.

Step 3 management: Most BRCA stems pivot on next best step—the answer is usually genetic counseling, MRI, RRBSO, or endometrial biopsy depending on context. Pattern-match these reflexes.

Board pearl: When the stem mentions fimbria, the answer involves salpingectomy and SEE-FIM pathology.

One-Line Recap

BRCA1/2 carriers require coordinated lifelong risk management: enhanced breast surveillance (annual MRI + mammography), risk-reducing bilateral salpingo-oophorectomy by age 35–40 (BRCA1) or 40–45 (BRCA2), consideration of risk-reducing mastectomy and chemoprevention, and cascade testing of first-degree relatives—all anchored by formal genetic counseling before and after testing.

Identify: Use validated familial risk tools (Tyrer-Cuzick, PREMM); refer for genetic counseling before testing; test the affected relative first; targeted single-site testing when familial variant is known.

Surveillance: Annual breast MRI from age 25, add mammography from age 30, alternating every 6 months; clinical breast exam every 6–12 months; no effective ovarian screening—steer toward RRBSO at recommended age.

Prophylaxis: RRBSO with SEE-FIM pathology by gynecologic oncologist provides the greatest mortality reduction; offer RRM for breast risk reduction; tamoxifen/AIs for ER-positive risk reduction; OCPs reduce ovarian cancer risk ~50% in young carriers.

Counseling pillars: Document informed consent; GINA covers health insurance/employment but not life/disability/LTC; do not act on a VUS; do not test minors; ensure cascade testing of first-degree relatives including men; provide HRT to premenopausal RRBSO patients without breast cancer history until natural menopause age.

Step 3 management: When in doubt on any BRCA vignette, the next best step is almost always "refer for genetic counseling"—every other intervention flows from that conversation.

Board pearl: The single highest-yield Step 3 BRCA fact: RRBSO before natural menopause is the only intervention with proven all-cause mortality benefit in BRCA carriers.